Second and further medical use claims provide companies and patent lawyers with interesting opportunities, as Caroline Pallard explains.
Under Article 54(5) of the European Patent Convention (EPC) 2000, known substances or compositions are deemed novel provided they are for any specific use in a medical method provided that such use is not comprised in the state of the art (ie, second or further medical use) (this is derived from Article 54[4] EPC 1973).
In 1983, the Enlarged Board of Appeal (G5/83) defined the way to formulate a second or further medical use of a substance or composition for the manufacture of a medicament for any “specified new and inventive therapeutic application”, based on Article 54 EPC 1973. Since then, case law decisions have primarily dealt with new diseases or conditions defining such second or further medical use.
In 2010, the Enlarged Board of Appeal (G02/08), redefined the way to formulate a second or further medical use of a substance or composition from Article 54(5) EPC 2000 and emphasised that “any specific use in a therapeutic method” as stated in Article 54(5) EPC 2000 could potentially be considered as a second or further medical use of a substance or composition, provided that such use was not comprised in the state of the art, thereby opening up the possibility to protect “any such specific use in a therapeutic method” as long as it meets all other EPC requirements.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Medical use claims, EPC 2000, second medical use, fulvestrant, Enlarged Board of Appeal